Detalhe da pesquisa
1.
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
Blood
; 141(13): 1584-1596, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375120
2.
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
Ann Hematol
; 103(1): 185-198, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37851072
3.
Prognostic Markers in the Era of Targeted Therapies.
Acta Haematol
; 147(1): 33-46, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37703841
4.
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Blood
; 138(19): 1843-1854, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34046681
5.
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Blood
; 137(2): 185-189, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259596
6.
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Br J Haematol
; 196(4): 947-953, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34865212
7.
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Blood
; 136(1): 93-105, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32202637
8.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood
; 136(10): 1134-1143, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32688395
9.
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Blood
; 132(5): 521-532, 2018 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29743179
10.
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Blood
; 131(21): 2357-2366, 2018 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29483101
11.
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
Blood
; 129(11): 1469-1479, 2017 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28049639
12.
Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations.
N Engl J Med
; 383(5): 498-500, 2020 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32726539
13.
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
Blood
; 128(15): 1940-1943, 2016 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27503501
14.
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Blood
; 138(18): 1768-1773, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34297826
15.
Cardiovascular adverse events of ibrutinib.
Blood
; 134(22): 1881-1882, 2019 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31778540
16.
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.
Blood
; 133(22): 2452-2455, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30917955
17.
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Am J Hematol
; 95(11): E310-E313, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32808680
18.
Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
Semin Hematol
; 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538512
19.
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
Blood Adv
; 8(4): 832-841, 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38163317
20.
Periarticular osteoporosis is a prominent feature in early rheumatoid arthritis: estimation using shaft to periarticular bone mineral density ratio.
J Korean Med Sci
; 28(2): 287-94, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23399828